logo
logo

CF Foundation Invests up to $14M in Effort to Solve Key Challenges to Gene Delivery in Cystic Fibrosis

Jun 17, 2020•over 5 years ago

Amount Raised

$14 Million

Bethesda

Description

Today the Cystic Fibrosis Foundation announced an investment of up to $14 million in 4D Molecular Therapeutics (4DMT) to develop a customized vehicle to deliver a healthy cystic fibrosis transmembrane conductance regulator (CFTR) gene into the lung cells of people with cystic fibrosis (CF). The delivery of genetic-based therapies is one of the key hurdles to developing an effective therapy for the more than 1,700 different mutations that cause CF, including nonsense and rare mutations.

Company Information

Company

Cystic Fibrosis Foundation Up To

Location

Bethesda, Maryland, United States

About

The CF Foundation launched its $500 million Path to a Cure initiative in October 2019. This initiative centers around three core strategies to address the underlying cause of CF: repairing broken CFTR protein, restoring CFTR protein when none exists, and fixing or replacing the underlying genetic mutation to address the root cause of CF. Each approach requires a different set of scientific tools and knowledge, leading the Foundation to bring together researchers and industry leaders from a range of disciplines to advance multiple areas of research in parallel, driving progress toward our goal to make CF stand for Cure Found. Innovators who are interested in pursuing programs in cystic fibrosis can learn about our specific funding opportunities here cff.org/PathtoaCure.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech